Alignment Healthcare, Inc. Common Stock
ALHC
$20.03
-16.72%
Alignment Healthcare is a next-generation Medicare Advantage platform that combines technology and clinical models to improve health outcomes for seniors. As a consumer-centric disruptor in the healthcare plans industry, it differentiates itself through direct-to-consumer marketing and a data-driven approach to care management. The current investor narrative centers on the company's accelerating revenue growth and path to profitability, bolstered by a favorable CMS Medicare Advantage payment increase for 2027 and its recent inclusion in the S&P SmallCap 600 index. However, insider selling and mixed quarterly earnings have fueled debate about valuation and sustainability.…
ALHC
Alignment Healthcare, Inc. Common Stock
$20.03
Related headlines
Investment Opinion: Should I buy ALHC Today?
Rating: Buy. Thesis: Alignment Healthcare offers a rare combination of accelerating revenue growth (44.4% YoY), improving margins, and a clear path to profitability, supported by favorable industry tailwinds and index inclusion, making it a compelling growth investment at a reasonable valuation.
Supporting Evidence: The trailing PS ratio of 0.99x is near the low end of its historical range (1.5x-13.4x), while the forward PS of 0.29x implies deep discount to future sales. Revenue growth is accelerating at 44.4% YoY, well above the healthcare plans industry median. The company achieved positive net income in Q2 and Q3 2025, and operating margin improved to -1.0% from -3.2% a year ago. Free cash flow turned positive on a TTM basis at $123.7M. Implied upside to analyst average EPS estimate of $1.60 using a forward PE of 32.9x suggests a target of $52.6, over 100% upside.
Risks & Conditions: The biggest risks are failure to achieve sustained profitability, margin compression, and insider selling. This Buy would downgrade to Hold if gross margins fall below 10% or net income remains negative for two consecutive quarters. It would upgrade to Strong Buy if the company reports positive net income for four consecutive quarters and revenue growth exceeds 50%. Valuation verdict: ALHC is undervalued relative to its growth trajectory, with a forward PS of 0.29x implying the market is not fully pricing in its revenue potential.
Sign up to view all
ALHC 12-Month Price Forecast
The AI assessment is bullish with medium confidence. ALHC's revenue growth is exceptional, and the path to profitability is becoming clearer with improving operating margins and positive TTM free cash flow. The valuation, particularly the forward PS of 0.29x, suggests the market is not fully pricing in the growth trajectory. However, the company remains unprofitable on a GAAP basis, and margin compression is a concern. The bullish stance would be upgraded to high confidence if the company reports two consecutive quarters of positive net income. Conversely, a downgrade to neutral would occur if gross margins fall below 10% or revenue growth decelerates below 30%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alignment Healthcare, Inc. Common Stock's 12-month outlook, with a consensus price target around $26.04 and implied upside of +30.0% versus the current price.
Average Target
$26.04
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$16 - $26
Analyst target range
Only 3 analysts cover ALHC, which is limited coverage typical for a mid-cap stock. The consensus recommendation is not explicitly provided, but the distribution from institutional ratings shows 2 Overweight/Buy ratings (JP Morgan, Piper Sandler), 1 Buy (TD Cowen), and 1 Neutral (UBS), indicating a moderately bullish tilt. The average EPS estimate for the next fiscal year is $1.60, with a range of $1.56 to $1.66. The average revenue estimate is $13.69 billion, with a range of $13.44 billion to $14.10 billion. No explicit price targets are given, but the implied upside based on the average EPS estimate and a forward PE of 32.9x (from valuation data) suggests a target price of approximately $52.6 (32.9 * $1.60), implying over 100% upside from the current price of $23.8. However, this is a rough calculation. The limited analyst coverage means higher uncertainty and less efficient price discovery. The wide range in revenue estimates ($13.44B to $14.10B) indicates moderate uncertainty about growth. Recent ratings actions include JP Morgan upgrading from Neutral to Overweight in November 2025, and Keybanc initiating Overweight in August 2025, signaling growing institutional confidence. The lack of a formal consensus target price and the small number of analysts suggest investors should rely more on fundamental analysis and monitor future coverage initiations.
Bulls vs Bears: ALHC Investment Factors
Alignment Healthcare presents a compelling growth story with accelerating revenue, improving profitability, and strong tailwinds from CMS payment increases and index inclusion. However, the company remains unprofitable, faces margin compression, and insider selling raises caution. The bull case currently has stronger evidence given the revenue momentum and path to profitability, but the key tension is whether the company can achieve sustained GAAP profitability while maintaining growth. If margins stabilize and net income turns positive consistently, the stock could re-rate significantly; if not, the elevated debt and cash burn could lead to downside.
Bullish
- Accelerating Revenue Growth: Revenue grew 44.4% YoY in Q4 2025 to $1.013 billion, with multi-quarter acceleration from 43.5% in Q3 2025 and 49.0% in Q2 2025. This top-line momentum is driven by Medicare Advantage membership expansion and favorable CMS payment increases.
- Path to Profitability Emerging: Net income improved from -$31.1M in Q4 2024 to -$11.0M in Q4 2025, and the company achieved positive net income in Q2 and Q3 2025. Operating margin improved to -1.0% from -3.2% a year ago, signaling a trajectory toward sustained profitability.
- Favorable CMS Payment Boost: The CMS announced a larger-than-expected Medicare Advantage payment increase for 2027, boosting revenue visibility across the sector. This directly benefits ALHC's premium revenue and supports continued growth.
- S&P SmallCap 600 Inclusion: ALHC was added to the S&P SmallCap 600 index in May 2026, which typically drives institutional buying and improves liquidity. This milestone increases the stock's visibility and investor base.
Bearish
- Negative GAAP Earnings: Trailing EPS is -$0.000185, and net income was -$11.0M in Q4 2025. Despite improvement, the company remains unprofitable on a GAAP basis, with a net margin of -1.1% in Q4 2025, below the industry average of 3-5%.
- Elevated Debt and Cash Burn: Debt-to-equity is 1.89, and free cash flow was -$66.6M in Q4 2025, though TTM FCF turned positive at $123.7M. The high leverage and past cash burn raise financial risk if growth slows.
- Insider Selling Signal: The vice chairman sold 25,000 shares in June 2026, adding to a pattern of insider selling. While part of a trading plan, it is a cautionary signal that insiders may be taking profits near the 52-week high.
- Margin Compression: Gross margin declined from 12.3% in Q4 2024 to 10.5% in Q4 2025, indicating pressure from medical cost trends. This could limit profitability even as revenue grows.
ALHC Technical Analysis
Alignment Healthcare is in a strong uptrend, with the stock up 74.9% over the past year and currently trading at 97.9% of its 52-week range (close to the high of $24.3). This positioning near the top of the range suggests bullish momentum but also potential overextension, as the stock has rallied sharply from its 52-week low of $11.625. The 1-year price change of +74.9% significantly outperforms the S&P 500's +19.1%, indicating strong relative strength. Short-term momentum is accelerating dramatically: the 1-month price change is +74.5% and the 3-month change is +26.9%, both outpacing the S&P 500's -1.25% and +13.56%, respectively. This divergence—where short-term gains far exceed the longer-term trend—signals a powerful near-term rally that may be driven by catalysts like the CMS payment boost and index inclusion, but also raises the risk of a mean-reversion pullback. The stock's beta of 1.052 indicates slightly higher volatility than the market, but not extreme. Key support lies near the 52-week low of $11.625, while resistance is at the 52-week high of $24.3. A breakout above $24.3 would signal continued upside momentum, while a breakdown below recent support near $20 could indicate a trend reversal. The 1-month relative strength of 75.7 versus the S&P 500 suggests the stock is overbought on a short-term basis.
Beta
1.05
1.05x market volatility
Max Drawdown
-44.1%
Largest decline past year
52-Week Range
$12-$25
Price range past year
Annual Return
+46.1%
Cumulative gain past year
| Period | ALHC Return | S&P 500 |
|---|---|---|
| 1m | +30.5% | +0.8% |
| 3m | -6.3% | +9.6% |
| 6m | -3.6% | +7.4% |
| 1y | +46.1% | +20.2% |
| ytd | -0.9% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALHC Fundamental Analysis
Revenue is growing rapidly, with the most recent quarterly revenue (Q4 2025) of $1.013 billion, up 44.4% year-over-year from $701 million in Q4 2024. The multi-quarter trend shows accelerating growth: Q3 2025 revenue was $994 million (up 43.5% YoY), Q2 2025 was $1.015 billion (up 49.0% YoY), and Q1 2025 was $927 million (up 47.5% YoY). The primary driver is premium revenue from Medicare Advantage members, with capitation revenue also contributing. This strong top-line growth supports the investment case, but the company remains unprofitable on a GAAP basis. Net income for Q4 2025 was -$11.0 million, though this improved from -$31.1 million in Q4 2024. Gross margin was 10.5% in Q4 2025, down from 12.3% in Q4 2024, indicating margin compression. However, operating margin improved to -1.0% from -3.2% a year ago, and the company achieved positive net income in Q2 and Q3 2025, suggesting a trajectory toward profitability. The net margin of -1.1% in Q4 2025 is narrow, and the industry average for healthcare plans is typically around 3-5%, so there is room for improvement. Balance sheet health is mixed: debt-to-equity is 1.89, which is elevated, but the current ratio of 1.74 indicates adequate liquidity. Free cash flow was -$66.6 million in Q4 2025, but trailing twelve-month FCF was $123.7 million, showing recent improvement. ROE is -0.4%, reflecting ongoing losses, but the company has $578 million in cash, providing a cushion. The FCF yield is not meaningful due to negative earnings, but the cash position reduces financial risk.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.44%
YoY Comparison
Gross Margin
+0.10%
Latest Quarter
Free Cash Flow
$123672000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALHC Overvalued?
Since net income is negative (trailing EPS -$0.000185), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 0.99x, while the forward PS (based on estimated revenue of $13.7 billion) is approximately 0.29x (market cap $3.91B / estimated revenue $13.69B). The large gap between trailing and forward PS reflects the market's expectation of significant revenue growth. Compared to the industry average PS ratio (not provided, but healthcare plans typically trade around 0.5-1.5x sales), ALHC's trailing PS of 0.99x is roughly in line. However, the forward PS of 0.29x suggests a deep discount to future sales, implying the market is pricing in substantial growth but also some skepticism about profitability. Historically, ALHC's PS ratio has ranged from about 1.5x to 13.4x over the past five years. The current trailing PS of 0.99x is near the low end of its historical range, which could indicate a value opportunity if growth materializes, or it could reflect deteriorating fundamentals. The PB ratio of 21.8x is extremely high, typical for asset-light healthcare companies, but not directly comparable to peers. The PEG ratio of 53.7x suggests the stock is expensive relative to its earnings growth, but given negative earnings, this metric is less relevant.
PE
-5337.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -99x~233x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ALHC's primary financial risk is its ongoing unprofitability, with a net margin of -1.1% in Q4 2025 and negative free cash flow of -$66.6M in that quarter. The debt-to-equity ratio of 1.89 indicates elevated leverage, and while the company has $578M in cash, continued losses could erode this cushion. Margin compression, with gross margin falling from 12.3% to 10.5% YoY, suggests medical cost trends are pressuring profitability. Revenue concentration in Medicare Advantage plans exposes the company to regulatory changes and membership retention risks.
Market & Competitive Risks: The stock's beta of 1.052 indicates slightly above-market volatility, making it sensitive to macro shifts. The trailing PS ratio of 0.99x is near the low end of its historical range (1.5x-13.4x), but the forward PS of 0.29x implies the market is pricing in substantial growth with skepticism. Competitive risks include larger players like UnitedHealth and Humana, which have greater scale and resources. The recent insider selling and limited analyst coverage (3 analysts) add to uncertainty. Regulatory risk from Medicare Advantage payment changes could impact revenue growth.
Worst-Case Scenario: If ALHC fails to achieve sustained profitability, faces membership losses, or encounters adverse regulatory changes, the stock could decline to its 52-week low of $11.625, representing a 51% downside from the current price of $23.8. In a severe scenario, historical max drawdown of -44.14% suggests a potential drop to around $13.3, consistent with the June 2026 low of $13.3. An investor could lose up to 51% in this adverse scenario.
FAQ
The primary risk is financial: the company is unprofitable with a net margin of -1.1% and has elevated debt-to-equity of 1.89, which could strain cash flows if growth slows. Competitive risk comes from larger players like UnitedHealth and Humana, which have greater scale. Regulatory risk is significant, as Medicare Advantage payment changes directly impact revenue. Company-specific risks include margin compression (gross margin fell from 12.3% to 10.5% YoY) and insider selling, which may signal a lack of confidence. The most severe risk is a failure to achieve profitability, which could lead to a 51% decline to the 52-week low of $11.625.
The 12-month forecast is bullish with a base case target of $20-$30 (45% probability), assuming revenue growth moderates to 30-35% and the company remains near breakeven. The bull case (30% probability) targets $30-$40, driven by sustained profitability and margin expansion. The bear case (25% probability) sees the stock falling to $12-$18 if margins compress and losses widen. The most likely scenario is the base case, where the stock trades in line with current multiples as the company makes steady progress toward profitability. Key catalysts include the next earnings report and the CMS final payment rule.
ALHC appears undervalued based on its growth trajectory. The trailing PS ratio of 0.99x is near the low end of its historical range of 1.5x-13.4x, and the forward PS of 0.29x implies the market is pricing in significant future revenue growth at a discount. Compared to the healthcare plans industry average PS of roughly 0.5-1.5x, ALHC's trailing PS is in line, but its forward PS is well below. The high PB ratio of 21.8x reflects the asset-light model and is not directly comparable. The valuation suggests the market is skeptical about profitability, but if the company delivers on earnings, the stock could re-rate significantly.
ALHC is a compelling buy for growth investors willing to tolerate near-term losses. The stock offers over 100% implied upside to the analyst average target of $52.6 based on forward EPS estimates, and the forward PS of 0.29x is deeply discounted relative to its growth rate. However, the company is not yet profitable, and insider selling is a cautionary signal. For investors with a 12-month horizon and high risk tolerance, ALHC is a good buy given the strong revenue momentum and favorable industry tailwinds. Conservative investors should wait for sustained profitability before entering.
ALHC is better suited for long-term investment given its growth stage and volatility. The stock has a beta of 1.052, indicating slightly above-market volatility, and the 1-month relative strength of 75.7 suggests it is overbought in the short term, raising the risk of a pullback. The company pays no dividend, so returns depend on capital appreciation. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to achieve sustained profitability and realize its growth potential. Short-term traders could capitalize on momentum, but the risk of mean reversion is high after the recent 74.5% monthly gain.